Defactinib and VS-6766 for the Treatment of Patients With Metastatic Uveal Melanoma
Status:
Recruiting
Trial end date:
2024-07-01
Target enrollment:
Participant gender:
Summary
This phase II trial studies the effect of combining defactinib and VS-6766 in treating
patients with uveal melanoma that has spread to other places in the body (metastatic). The
way cells communicate with one another (different cell signaling pathways) are overactive in
uveal melanoma tumor cells. Giving defactinib together with VS-6766 may block pathways that
are important for the growth of uveal melanoma cells, and may result in shrinkage or
stabilization of the cancer and prolonged time to disease progression and survival.